Skip to main content

PEPTICHIP: Streamlined identification of tumour neoantigens for personalised anti-cancer immunotherapy

Project description

The key to unlock your immune response to cancer may be on the horizon

Cancer immunotherapy harnesses a person's immune system to fight cancer either by stimulating the patient's own immune system or by providing man-made immune system components. It was voted 'breakthrough of the year’ by Science magazine in 2013. However, despite its potential, patient response rates vary and often only a small portion respond favourably to a given treatment. Personalised cancer immunotherapy could unlock the potential but current methods are expensive and time-consuming. PeptiCHIP has developed a system to identify and purify patient-specific neoantigens (newly formed antigens that have not been previously recognised by the immune system) quickly and easily. EU funding is helping partners establish the business to make it available to millions of patients worldwide.

Call for proposal

ERC-2019-PoC
See other projects for this call

Host institution

HELSINGIN YLIOPISTO
Address
Yliopistonkatu 3
00014 Helsingin Yliopisto
Finland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 150 000

Beneficiaries (1)

HELSINGIN YLIOPISTO
Finland
EU contribution
€ 150 000
Address
Yliopistonkatu 3
00014 Helsingin Yliopisto
Activity type
Higher or Secondary Education Establishments